Long-Term Efficacy of Baricitinib in Alopecia Areata: 3-Year Results from BRAVE-AA1 and BRAVE-AA2

    Maryanne M. Senna, Arash Mostaghimi, Manabu Ohyama, Rodney Sinclair, Chiara Chiasserini, Yves Dutronc, Najwa Somani, Guanglei Yu, Jill Kolodsick, Lucy Liu
    Image of study
    TLDR Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
    The study evaluates the long-term efficacy of baricitinib in treating severe alopecia areata over three years, focusing on patients who responded to treatment by Week 52 with a SALT score of ≤20. Results from the BRAVE-AA1 and BRAVE-AA2 trials show that 89.1% of patients on 4mg and 83.6% on 2mg maintained this level of scalp hair regrowth by Week 152. Additionally, significant improvements in eyebrow and eyelash regrowth were observed, with 80% and 66.7% of 4mg and 2mg patients, respectively, achieving notable eyebrow regrowth, and 80.9% and 78.1% achieving eyelash regrowth. These findings support the long-term use of baricitinib for maintaining hair regrowth in severe alopecia areata.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 11 results

    Related Research

    1 / 1 results